ArticleTobacco induced diseases2026
Awareness and perceptions of nicotine replacement therapy among adults in Saudi Arabia: A cross-sectional study.
Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNicotine replacement therapies (NRTs) are established evidence-based interventions for smoking cessation. In Saudi Arabia, where tobacco use remains a significant public health concern, understanding public awareness, perceptions, and motivations related to NRT use is essential for designing effective cessation strategies. This study aimed to assess awareness, perceptions, motivation to quit smoking, and self-reported nicotine dependence related to NRT use among adults in Saudi Arabia.
methodsBetween February and May 2025, a cross-sectional online survey was distributed via social media platforms to adults aged ≥18 years across Saudi Arabia. The survey comprised four domains: demographics, NRT awareness/perception, the Questionnaire on Motivation to Quit (Q-MAT; 4 scored items, range 0-20), and the Nicotine Dependence Syndrome Scale (NDSS; 16 items, 5-point Likert scale). The Q-MAT and NDSS were administered only to current smokers. Internal consistency was assessed using Cronbach's alpha. Chi-squared tests examined associations between demographic variables and NRT awareness. Binary logistic regression identified predictors of NRT awareness. Independent samples t-tests compared NDSS scores by motivation level.
resultsAmong 425 eligible participants, 72.5% were male, and the largest proportion were aged 25-34 years (43.3%). Overall, 89.1% of the participants were aware of NRTs. However, 49.3% were unsure about the most effective NRT type, and 37.3% were uncertain about its side effects. The Q-MAT (Cronbach's α=0.729) yielded a mean motivation score of 12.3 ± 5.8 (out of 20), with 44.4% classified as highly motivated. The NDSS (α=0.876) revealed moderate-to-high dependence (overall mean 2.94 ± 0.78), with the Drive subscale scoring highest (3.25 ± 1.09). Logistic regression showed male gender was a significant predictor of NRT awareness (OR=1.98; 95% CI: 1.01-3.89; p=0.048). Two-thirds of participants (66.0%) supported NRT integration into academic curricula.
conclusionsWhile general NRT awareness was high among our sample of Saudi adults, significant knowledge gaps persist regarding its effectiveness and safety. High motivation to quit combined with moderate-to-high nicotine dependence underscores the importance of this area for future investigation. Longitudinal and interventional studies are needed to determine whether targeted education, improved access to cessation support, and integration of smoking cessation content into healthcare training programs can effectively address these gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.